Related Experiment Video

Updated: Jun 15, 2026

Electrocardiogram Recordings in Anesthetized Mice using Lead II
04:16

Electrocardiogram Recordings in Anesthetized Mice using Lead II

Published on: June 20, 2020

Antimicrobial agents-associated with QT interval prolongation

Fernando Bril1, Claudio Daniel Gonzalez, Guillermo Di Girolamo

  • 1Department of Internal Medicine, Centro de Educación Médica e Investigaciones Clínicas Dr. Norberto Quirno, Buenos Aires, Argentina. bfernando@fibertel.com.ar

Current Drug Safety
|March 10, 2010
PubMed

Insights

Certain anti-infective drugs can prolong the QT interval, increasing the risk of Torsades de Pointes (TdP) arrhythmia. Awareness of these drugs, their interactions, and patient factors is crucial for safe prescribing.

Area of Science:

  • Pharmacology
  • Cardiology
  • Infectious Diseases

Background:

  • QT interval prolongation is a significant cause for drug market withdrawal due to its link with Torsades de Pointes (TdP).
  • The potential for antimicrobial agents to induce TdP is often underestimated despite their widespread use.
  • Several classes of anti-infective drugs, including macrolides, quinolones, and azoles, are frequently associated with this adverse effect.

Purpose of the Study:

  • To review the role of anti-infective drugs in causing QT interval prolongation.
  • To highlight the mechanisms underlying drug-induced QT prolongation.
  • To discuss potential drug interactions and patient-specific risk factors for TdP.

Main Methods:

  • Literature review focusing on anti-infective agents and their association with QT prolongation and TdP.
  • Analysis of drug interaction data and patient predisposing factors.
  • Synthesis of information on QT prolongation mechanisms.

Main Results:

  • Anti-infective drugs, particularly macrolides, quinolones, and azoles, are implicated in QT prolongation and TdP.
  • The risk, though low with single therapy, increases due to extensive drug use and potential interactions.
  • Pharmacokinetic and pharmacodynamic interactions can elevate the risk of TdP.

Conclusions:

  • Physicians need to be aware of anti-infective drugs that prolong the QT interval.
  • Understanding drug interactions and patient risk factors is essential for preventing TdP.
  • Comprehensive knowledge of anti-infective drug effects on cardiac rhythm is vital for patient safety.

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration01:23

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...